Table 2 Subgroup analyses of OS in bTMB high and bTMB low NSCLC patients
Variable | No. of cohorts | No. of patients | bTMB high | bTMB low | ||||
|---|---|---|---|---|---|---|---|---|
bTMB high /bTMB low | Pooled HR (95% CI) | P | I2 (%) | Pooled HR (95% CI) | P | I2 (%) | ||
Line of therapy | ||||||||
 1 | 4 | 466/1222 | 0.63 (0.50–0.79) | < 0.01 | 0 | 0.97 (0.79–1.19) | 0.79 | 51.8 |
 ≥2 | 2 | 221/573 | 0.62 (0.45–0.84) | < 0.01 | 0 | 0.68 (0.56–0.82) | < 0.01 | 0 |
Therapy regimen | ||||||||
 Anti-PD-L1 vs CT | 4 | 455/1269 | 0.67 (0.54–0.83) | < 0.01 | 0 | 0.83 (0.66–1.05) | 0.12 | 63.3 |
 Anti-PD-L1 plus anti-CTLA-4 vs CT | 1 | 134/389 | 0.49 (0.32–0.75) | < 0.01 | N/A | 1.16 (0.93–1.45) | 0.19 | N/A |
 Anti-PD-1 plus CT vs CT | 1 | 98/137 | 0.61 (0.36–1.05) | 0.07 | N/A | 0.64 (0.41–0.99) | 0.05 | N/A |
Type of NGS panel | ||||||||
 Foundation one | 3 | 308/875 | 0.64 (0.49–0.85) | < 0.01 | 0 | 0.80 (0.58–1.09) | 0.15 | 67.8 |
 Gardant OMNI | 3 | 379/920 | 0.61 (0.48–0.78) | < 0.01 | 0 | 0.93 (0.71–1.23) | 0.62 | 66.7 |
PD-L1 expression | ||||||||
 Unselected for PD-L1 | 5 | 600/1493 | 0.61 (0.50–0.74) | < 0.01 | 0 | 0.82 (0.65–1.05) | 0.12 | 74.5 |
 PD-L1 positive | 1 | 87/302 | 0.75 (0.41–1.36) | 0.34 | N/A | 1.07 (0.77–1.48) | 0.68 | N/A |
Cut-off value (mut/meg) | ||||||||
 16 | 3 | 308/875 | 0.64 (0.49–0.85) | < 0.01 | 0 | 0.80 (0.58–1.09) | 0.15 | 67.8 |
 Others | 3 | 379/920 | 0.61 (0.48–0.78) | < 0.01 | 0 | 0.93 (0.71–1.23) | 0.62 | 66.7 |